



Altimune to Participate at Two Upcoming Investor Conferences

October 17, 2023 at 7:30 AM EDT

GAITHERSBURG, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

- **H.C. Wainwright 7th Annual NASH Investor Conference (Virtual Conference)**
Tuesday, October 24, 2023
Presentation at 10:00 am Eastern Time
- **H. C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference**
Wednesday, October 25, 2023
Fireside chat at 3:00 pm Eastern Time

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Altimune Investor Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

Media Contact:

Danielle Cantey
Evoke Canale
Phone: 619-826-4657
danielle.cantey@evokegroup.com



Source: Altimune, Inc